Prime Medicine, Inc.

Prime Medicine, Inc. is a U.S.-based biotechnology company developing Prime Editing, a gene-editing platform designed to make precise DNA changes for genetic diseases and other disorders. The company’s pipeline includes wholly owned in vivo programs, an ex vivo cell-therapy collaboration, and early discovery efforts, with operations centered in Cambridge, Massachusetts.

−4 340,0 %

−4 342,4 %

+55,3 %

4.84

— Prime Medicine, Inc.
	%
Prime Editing platform	0% Core gene-editing technology used to create precise DNA edits across multiple therapeutic programs.
Wholly owned in vivo programs	45% Liver-directed genetic medicine programs targeting Wilson Disease, AATD, and related indications.
Clinical-stage PM359 program	20% Program for chronic granulomatous disease intended to validate Prime Editing in humans.
Collaborative ex vivo programs	20% Partnered cell-engineering work with BMS applying Prime Editing to T-cell therapies.
Discovery and enabling technologies	15% Early-stage research, LNP delivery, manufacturing, and IND-enabling development work.

Prime Medicine does not sell commercial products; its current customers are collaboration partners and, in the future,...

Strategic collaboration partnersprimary
Pharmaceutical and biotech partners that pay for access to Prime Editing capabilities, shared development, or licensed programs.
Rare disease patientsprimary
Patients with defined genetic disorders such as Wilson Disease, AATD, and CGD who would use approved therapies if developed.
Oncology and immunology partnerssecondary
Partners and future treatment centers involved in ex vivo T-cell engineering and related cell therapy applications.
Research and translational ecosystemsecondary
Academic, foundation, and disease-advocacy collaborators that support discovery, data generation, and program advancement.

Prime Medicine is headquartered in Cambridge, Massachusetts and operates as a U.S.-based development-stage biotech...

•Headquartered in Cambridge, Massachusetts
•U.S. clinical and regulatory focus for lead programs
•Potential future trial and partner activity in Europe
•Collaborations may broaden geographic reach without owned sales force
•No commercial manufacturing footprint disclosed

The company’s strategy is to advance Prime Editing from platform validation into clinical development, starting with...

Advance liver-directed in vivo programsshort-term

Wilson Disease and AATD are core franchise opportunities and near-term clinical catalysts.

Validate Prime Editing in humansshort-term

Clinical proof-of-concept supports platform credibility and future partnering.

Expand through collaborationsmedium-term

Partnerships can add capabilities and funding without overextending internal resources.

Build development infrastructuremedium-term

Clinical-stage execution requires manufacturing, quality, and regulatory readiness.

Prime Medicine faces the typical risks of a pre-commercial biotech: clinical failure, regulatory delays, and dependence...

critical

Clinical development failure

Prime Editing programs are still in preclinical or early clinical stages and may not translate into approved therapies.

Scope: Lead liver programs, PM359, and future pipeline assets
Materiality: high

high

Regulatory delay or non-approval

Gene-editing therapies require extensive FDA/EMA review and may need additional data or longer follow-up.

Scope: IND/CTA filings, BLA path for PM359, future approvals
Materiality: high

high

Financing and going-concern pressure

The company has no product sales and depends on external funding to sustain development.

Scope: Operating runway and program continuity
Materiality: high

high

Partner concentration and collaboration execution

A meaningful portion of value creation depends on successful third-party collaborations and license arrangements.

Scope: BMS collaboration and future strategic deals
Materiality: medium

medium

Supply chain and geopolitical exposure

Preclinical and clinical development may rely on China-based suppliers or service providers that could be restricted.

Scope: Raw materials, testing, and outsourced development services
Materiality: medium

ASC 606 collaboration revenue

Can shift revenue between periods without changing cash receipts

Stock-based compensation valuation

Can materially affect operating expenses and equity compensation cost

Accrued research and development

Can change reported R&D expense and liabilities

Contingent collaboration milestones

Creates off-balance-sheet style economic obligations and expense uncertainty

Prime Medicine, Inc.

Clinical development failure

Regulatory delay or non-approval

Financing and going-concern pressure

Partner concentration and collaboration execution

Supply chain and geopolitical exposure

Beam Therapeutics Inc.

Editas Medicine, Inc.

PRECISION BIOSCIENCES INC

Maze Therapeutics, Inc.

Advanced Biomed Inc.

Metagenomi Therapeutics, Inc.